Ligand Funds AvenCell CAR T Pipeline

Company Ligand Pharmaceuticals / AvenCell Therapeutics Event Type Royalty Financing and Series C Investment Modality Switchable Allogeneic CAR-T Cell Therapy Asset AVC-201 / AVC-203 Target CD123 (AVC-201) Disease Area Acute Myeloid Leukemia / B-Cell Malignancies Summary Ligand committed up to $47 million to AvenCell Therapeutics.…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

GSK Acquires Nuvalent for $10.6B
Curium Agrees to Acquire Lantheus for Up to $8 Billion
Typewriter Launches with $56 Million for All-RNA Gene Insertion
Ligand Funds AvenCell CAR T Pipeline